In addition, multivariable analysis of a smaller cohort of intermediate-risk AML patients (defined by cytogenetics alone) identified ASXL1 and FLT3-ITD as factors predicting lower chances of achieving CR113. The gene discussed is FLT3; the disease is acute myeloid leukemia.